NCT03464903View on ClinicalTrials.gov

Study of ALS Reversals 2: Genetic Analyses

CompletedOBSERVATIONAL

Enrollment

26

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

Amyotrophic Lateral SclerosisProgressive Muscular Atrophy

Trial Locations (1)

27705

Duke ALS Clinic / DUSOM Dept of Neurology / DUHS, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

CReATe Consortium (funded by NIH/NCATS/NINDS)

UNKNOWN

lead

Duke University

OTHER

NCT03464903 - Study of ALS Reversals 2: Genetic Analyses | Biotech Hunter | Biotech Hunter